IMPORTANCE Chronic cough is a debilitating, often multifactorial problem. Vagal neuropathy has been proposed as a cause for a fraction of these cases. There are certain features that support the clinical diagnosis of vagal neuropathy. It is hypothesized that patients with neurogenic cough who have vocal fold motion asymmetry (VFMA) on laryngoscopy will be more likely to respond to gabapentin.
N eurogenic cough is considered to be a symptom of vagal neuropathy (VN). In previously published studies, neurogenic cough was suspected as a diagnosis of exclusion following consideration of a wide differential. [1] [2] [3] The initial management of a newly diagnosed chronic cough varies, but commonly used approaches include pulmonary function tests, noncontrast computed tomography of the sinuses, an empirical trial of laryngeal irritant avoidance with proton pump inhibitors, and pH testing. When imaging, testing, and medication trials fail to reveal a source of the cough, neurogenic cough is often considered. There is an emerging body of literature theorizing that chronic cough may be one symptom in a constellation of symptoms attributable to VN. Proponents of this theory describe a lingering cough, globus, vocal fold paresis, and dysphagia that follow an upper respiratory tract infection, which is termed postviral vagal neuropathy (PVVN). 1, 4, 5 The proposed possible mechanisms of cough reflex potentiation in PVVN include a lowering of the threshold for activation, laryngeal dysesthesias, and increasing the gain of the cough reflex at the brainstem level. 3 Other stimuli, such as laryngopharyngeal reflux, perfumes, cold or warm air, talking, laughing, singing, deep breathing, or change in body position, can trigger coughing paroxysms in these patients. 6 Although neurogenic cough associated with PVVN is considered a disordered sensory phenomenon, 49% to 71% of patients have a concurrent motor neuropathy. 4, 7 The initial description of PVVN included the association with an antecedent upper respiratory tract illness prompting the theory of viral cause, 5 but a definitive viral causation has not been established and the term PVVN limits the discussion to neuropathies suspected to be viral in origin. A broader category of VN is used in this article to include a constellation of motor and sensory symptoms (ie, a combination of globus sensation, chronic dry cough, vocal fold motion asymmetry [VFMA] , and dysphagia). Several neuromodulators have been successfully used to treat cough related to VN. 2, [8] [9] [10] [11] Gabapentin, an analog of γ-aminobutyric acid, inhibits voltage-gated, calcium-channelmediated release of neurotransmitters. 3 A number of studies support its efficacy including a prospective, randomized, doubleblind, placebo-controlled trial. 11 However, not every patient responds to treatment with gabapentin. Given the potential adverse effects of the medication and delay in arriving at beneficial treatment, identifying likely responders is a desirable goal in this clinical arena. It is hypothesized that the presence of VFMA on laryngoscopy in patients with chronic cough is associated with an increased likelihood of response to gabapentin.
Methods
Patients who presented to the University of Washington Medical Center Laryngology Clinic from January 1, 2013, to September 1, 2015, with a primary International Classification of Diseases, Ninth Revision diagnosis of chronic cough were identified from internal records. Approval for a retrospective medical records review was obtained from the University of Washington Medical Center Institutional Review Board. A waiver of informed consent was granted by the institutional review board owing to the minimal risk of the retrospective medical records review.
Patients who had a chronic cough (duration >8 weeks) and those who received a prescription for gabapentin were included for study. Patients who did not undergo videostroboscopy, with follow-up of less than 1 month, and who did not participate in at least 1 speech therapy session were excluded. Medical records were reviewed for demographics, cough-related history of present illness, physical and videostroboscopic examination findings. Validated questionnaires of the Voice Handicap Index-10 (score range, 0-40; normal values, ≤11) 12 and Reflux Symptom Index (score range, 0-45; normal, <13) 13 were recorded at the initial evaluation visit for chronic cough. All patients were seen in a multidisciplinary clinic including an experienced speechlanguage pathologist. Flexible videostroboscopy was performed by one of us (A.M.) in conjunction with the speech-language pathologist and, if present at the visit, a training physician. Videostroboscopy tasks included alternating pronunciation of the letter e and sniff, connected speech, and humming or whistling of a common song verse to assess for vocal fold motion. Fatigue with repetitive maneuvers was used at the discretion of the team to further assess motion asymmetries. Consensus among the multidisciplinary team on VFMA was obtained after review of the video during the clinic visit and was based on speed and extent of vocal fold abduction. This consensus was documented in the visit note. For the purposes of this retrospective review, mention of asymmetry on the examination note was defined as positive for VFMA. Patients were not routinely referred for laryngeal electromyography. Gabapentin therapy was prescribed based on clinical suspicion for VN, and it was the only medication change made in the patient's treatment during that visit. All patients were given a prescription for an initial gabapentin dose of 100 mg twice daily, and increased weekly by 100 mg, dividing larger doses into administration 3 times daily. The final dose was titrated to response or adverse effects with a maximum daily dose of 1800 mg. Patients were classified as complete responders (resolution of cough symptoms), partial responders (improvement but no resolution), and nonresponders (no improvement) based on their reported symptoms as documented in the medical record.
Statistical Analysis
Statistical analysis was performed first by comparing the 3 groups of complete, partial, and nonresponders and then again by dividing patients into responder and nonresponder categories. Medical history, physical examination, VFMA, and doses limited by adverse effects were defined as categorical variables and compared via the Fisher exact test. Daily maximum dose was a normally distributed continuous variable evaluated by analysis of variance. Nonparametric continuous variables with dichotomous categories were evaluated with the Wilcoxon rank sum test and continuous variables with more than 2 categories were evaluated using nonparametric 1-way analysis of variance (Kruskal-Wallis test). Significance was assessed at α = .05. SAS Enterprise, version 6.3 (SAS Institute Inc) was used to perform all analyses.
Results
Of the 204 patients with the primary diagnosis of cough, VN was diagnosed in 27 patients and gabapentin was prescribed. One patient was lost to follow-up and 1 patient did not fill his prescription because he changed his mind and did not want to try gabapentin therapy. Twenty-five patients (15 women) were available for analysis; mean (SD) age was 57 (11.8) years. Nine patients (36%) did not respond to gabapentin therapy, 6 patients (24%) had some improvement but not resolution of cough with gabapentin, and 10 (40%) individuals were complete responders. Sixteen of 25 patients (64%) had either a complete or partial response to gabapentin therapy. There was no statistically significant difference in the mean maximum daily gabapentin dose or number of patients who had their dose limited by adverse effects ( Table 1) . Dose escalation was limited by decreased mental acuity (4 patients), drowsiness (2), headaches and nausea (1), and fatigue (1). One of the partial responders was able to continue therapy at a lower dose that resolved adverse effects. She had continued cough improvement but not resolution of symptoms.
Odds ratios (ORs) for the details of cough history of the present illness, including acute onset, associated pain or globus, or trigger by noxious stimuli, were not statistically significant between responders and nonresponders ( Table 2 ). In addition, the ORs for patients with asthma, chronic sinusitis, traditional gastroesophageal reflux disease symptoms, previous proton pump inhibitor therapy, or current angiotensin-converting enzyme inhibitor therapy were not significant ( Table 2 ). The median difference of the initial visit Voice Handicap Index-10 score between responders and nonresponders was 1 (range, −6 to 8) and, for the Reflux Symptom Index score, the median difference was 8 (range, −2 to 15). Videostroboscopy was performed in all patients and the medical records procedure reports were reviewed for mention of VFMA. The presence of VFMA on examination was observed in 15 of 16 (94%) patients compared with 5 of 9 (55%) patients in the nonresponder group. The difference in the frequency of VFMA between responders and nonresponders was 38% (95% CI, 18%-58%).
Discussion
Although VN is an uncommon cause of chronic cough, it can be beneficial to identify patients with neurogenic cough, because pharmacologic therapy has been well demonstrated to be effective in these patients. [1] [2] [3] [4] 7, 11, 14, 15 incidence of paresis in patients with PVVN; however, only 53% of the patients had a persistent cough as part of their symptoms. This study included patients with PVVN who had voice, cough, and sensory phenomena; the proportion of patients with cough who had motion abnormalities was not specifically mentioned. Although motion or vibratory abnormalities are not reliable predictors of the side of injury, both Simpson et al 16 and Woo et al 17 showed that physicians' diagnosis of VFMA on stroboscopy had an 83% and 88% correlation, respectively, with L-EMG-demonstrated injury. Taken as part of the clinical picture, VFMA may support considering VN as the source of chronic cough instead of a diagnosis of exclusion. The association of motor neuropathy with response to therapy was first noted by Lee and Woo in 2005. 7 In that study, patients with laryngeal irritability symptoms, including chronic cough, throat clearing, laryngospasm, and dysphagia, were evaluated with videostroboscopy and L-EMG was offered to patients in whom motor neuropathy was suspected. The authors divided their case series into 3 groups for the purposes of evaluation. Group 1 included 4 patients with known injury to the recurrent laryngeal nerve (RLN) or superior laryngeal nerve (SLN). Group 2 (n = 16) had evidence on videostroboscopy of VFMA or RLN/SLN neuropathy on L-EMG. Group 3 (n = 8) had no evidence on videostroboscopy or L-EMG of RLN/SLN neuropathy. Eighty percent of the patients with evidence of motor neuropathy on L-EMG or videostroboscopy had a response to gabapentin compared with 38% of those without evidence of motor neuropathy. Videostroboscopic and L-EMG findings were not reported separately, making it difficult to determine the association between gabapentin response and videostroboscopic findings alone. Although demonstrated to be useful in neurogenic cough workup, L-EMG may be a barrier to further management. Many patients opt not to undergo the procedure owing to concerns for discomfort and, depending on the number of available L-EMG clinics, scheduling may delay the initiation of pharmacotherapy. Our data show that the odds of improvement with gabapentin therapy are higher when VFMA is present on videostroboscopy without the use of L-EMG. Thus, during the initial clinical evaluation, videostroboscopy, when considered in the clinical context, may inform the decision to pursue gabapentin therapy. The odds of asthma, traditional gastroesophageal reflux disease symptoms, and previous proton pump inhibitor therapy were not significantly different between responders and nonresponders. Many patients underwent pulmonary function tests and reflux testing prior to evaluation, but these were not uniformly conducted in the group. For the 204 patients evaluated for chronic cough, pulmonary function tests and pH testing were performed in those whose clinical picture warranted the examinations. Any physician-initiated treatments, such as medications or recommended procedures, were performed in isolation so that their effect could be observed. However, this process does not eliminate the potential for patient-initiated interventions, such as avoidance of laryngeal irritants, use of over-the-counter medications, and lifestyle changes that may have confounded our results. Pretreatment Reflux Symptom Index and Voice Handicap Index-10 questionnaire scores were not significantly different between the groups. Cough questionnaires were provided to the patients; however, as a part of our standard patient intake questionnaires, our clinic administers a shortened version of the Leicester Cough Questionnaire (LCQ). 18 Although our questionnaire contains 10 of the 19 questions from the Leicester Cough Questionnaire, it has not been separately validated; thus, the raw data were not presented.
Limitations
Our study is limited by a small sample size, making it unable to identify other associations of successful gabapentin therapy in the history of the present illness that many have proposed to be a clinical indicator of VN. In addition, the inherent limitations of retrospective data collection are present in this study, specifically, the use of physicians' annotations of subjective patient-reported cough improvement and use of a modified version of a validated cough questionnaire. The prospective use of a Likert cough severity scale, a validated cough qualityof-life questionnaire, or a previously validated visual analog scale would provide a more detailed and reliable account of cough severity. Some studies have used a cough monitor to objectively measure cough frequency. 9,10 Without a control group, improvement related to the natural course of chronic cough thought to be related to VN could not be identified; however, this design was beyond the scope of our study. Finally, although only one change to management was made at each visit, the retrospective nature of this study did not allow for standardization of management of potential comorbid asthma, pulmonary disease, laryngopharyngeal reflux, or sinusitis.
Conclusions
In patients with a clinical diagnosis of neurogenic cough suspected to be related to VN, the odds of response to gabapentin are higher with the presence of VFMA on videostroboscopy. 
